Video

Q&A With Robert Giugliano From Brigham and Women's: PCSK9 Inhibitors Provide Hope for Cardiac Patients

Author(s):

It was less than two decades ago that researchers uncovered the role of PCSK9 in a person's body. In just the past few months two new medications have been developed that could go a long way in helping win the fight against bad cholesterol.

It was less than two decades ago that researchers uncovered the role of PCSK9 in a person's body. In just the past few months two new medications have been developed that could go a long way in helping win the fight against bad cholesterol.

Robert Giugliano, MD, from Brigham and Women's Hospital discussed the early stages of the medication and what it can mean for treatment of patients going forward during the European Society of Cardiology's annual meeting in London.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.